These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 7767913)

  • 1. Plasma DNA as a marker of cancerous cell death. Investigations in patients suffering from lung cancer and in nude mice bearing human tumours.
    Fournié GJ; Courtin JP; Laval F; Chalé JJ; Pourrat JP; Pujazon MC; Lauque D; Carles P
    Cancer Lett; 1995 May; 91(2):221-7. PubMed ID: 7767913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude mice.
    Pinski J; Schally AV; Halmos G; Szepeshazi K; Groot K; O'Byrne K; Cai RZ
    Br J Cancer; 1994 Nov; 70(5):886-92. PubMed ID: 7947094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
    Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
    Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers and IL-2R in lung cancer.
    Marino P; Preatoni A; Fonticoli L; Parodi M; Tarolo GL
    Recenti Prog Med; 1990 Nov; 81(11):702-4. PubMed ID: 1962891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum tumour markers in lung cancer.
    Hansen M
    Scand J Clin Lab Invest Suppl; 1991; 206():93-101. PubMed ID: 1658919
    [No Abstract]   [Full Text] [Related]  

  • 6. Cyfra 21-1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity, and prognostic role.
    Wieskopf B; Demangeat C; Purohit A; Stenger R; Gries P; Kreisman H; Quoix E
    Chest; 1995 Jul; 108(1):163-9. PubMed ID: 7541742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elastase levels in small and non-small cell lung carcinoma.
    Güner G; Kirkali G; Baskin Y; Karlikaya C; Akkoçlu A
    Biochem Soc Trans; 1993 Aug; 21 ( Pt 3)(3):305S. PubMed ID: 8224451
    [No Abstract]   [Full Text] [Related]  

  • 8. Value of tumour and inflammatory markers in lung cancer.
    Oremek GM; Sauer-Eppel H; Bruzdziak TH
    Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical usefulness of a new tumor marker CYFRA21-1 in patients with lung cancer].
    Li R; Li R; Wang Y
    Zhonghua Jie He He Hu Xi Za Zhi; 1998 Jan; 21(1):26-9. PubMed ID: 11263296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating DNA is a useful prognostic factor in patients with advanced non-small cell lung cancer.
    Sirera R; Bremnes RM; Cabrera A; Jantus-Lewintre E; Sanmartín E; Blasco A; Del Pozo N; Rosell R; Guijarro R; Galbis J; Sánchez JJ; Camps C
    J Thorac Oncol; 2011 Feb; 6(2):286-90. PubMed ID: 21252717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The diagnostic and prognostic value of ProGRP in lung cancer.
    Nisman B; Biran H; Ramu N; Heching N; Barak V; Peretz T
    Anticancer Res; 2009 Nov; 29(11):4827-32. PubMed ID: 20032442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Technical performance and diagnostic utility of the new Elecsys neuron-specific enolase enzyme immunoassay.
    Muley T; Ebert W; Stieber P; Raith H; Holdenrieder S; Nagel D; Fürst H; Roth HJ; Luthe H; Blijenberg BG; Gurr E; Uhl W; von Pawel J; Drings P
    Clin Chem Lab Med; 2003 Jan; 41(1):95-103. PubMed ID: 12636057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple sequential biomarkers in monitoring patients with carcinoma of the lung.
    Aroney RS; Dermody WC; Aldenderfer P; Parsons P; McNitt K; Marangos PJ; Whitacre MY; Ruddon RW; Wiernik PH; Aisner J
    Cancer Treat Rep; 1984 Jun; 68(6):859-66. PubMed ID: 6329508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of serum tumor markers in patients with lung cancer.
    Hatzakis KD; Froudarakis ME; Bouros D; Tzanakis N; Karkavitsas N; Siafakas NM
    Respiration; 2002; 69(1):25-9. PubMed ID: 11844959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pro-gastrin-releasing peptide (ProGRP)--a useful marker in small cell lung carcinomas.
    Stieber P; Dienemann H; Schalhorn A; Schmitt UM; Reinmiedl J; Hofmann K; Yamaguchi K
    Anticancer Res; 1999; 19(4A):2673-8. PubMed ID: 10470218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of histologic type and smoking status on interpretation of serum carcinoembryonic antigen value in non-small cell lung carcinoma.
    Okada M; Nishio W; Sakamoto T; Uchino K; Yuki T; Nakagawa A; Tsubota N
    Ann Thorac Surg; 2004 Sep; 78(3):1004-9; discussion 1009-10. PubMed ID: 15337038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
    Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T
    Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYFRA 21-1 enzyme-linked immunosorbent assay. Evaluation as a tumor marker in non-small cell lung cancer.
    Lai RS; Hsu HK; Lu JY; Ger LP; Lai NS
    Chest; 1996 Apr; 109(4):995-1000. PubMed ID: 8635383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR array: uses in the detection of plasma EGFR mutations in non-small cell lung cancer patients.
    Yam I; Lam DC; Chan K; Chung-Man Ho J; Ip M; Lam WK; Chan TK; Chan V
    J Thorac Oncol; 2012 Jul; 7(7):1131-40. PubMed ID: 22610259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated plasma thymosin-alpha1 levels in lung cancer patients.
    Sasaki H; Fujii Y; Masaoka A; Yamakawa Y; Fukai I; Kiriyama M; Saito Y; Matsui H
    Eur J Cardiothorac Surg; 1997 Dec; 12(6):885-91. PubMed ID: 9489875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.